Assetmark Inc. Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by on Aug 11th, 2023

Assetmark Inc. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,369 shares of the biopharmaceutical company’s stock after buying an additional 306 shares during the quarter. Assetmark Inc.’s holdings in Alnylam Pharmaceuticals were worth $875,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of ALNY. Raymond James Financial Services Advisors Inc. raised its position in Alnylam Pharmaceuticals by 9.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after buying an additional 1,017 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $1,268,000. Panagora Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 96.4% during the 1st quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares during the last quarter. Great West Life Assurance Co. Can increased its position in shares of Alnylam Pharmaceuticals by 21.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 10,892 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 1.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares during the last quarter. Hedge funds and other institutional investors own 94.43% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $185.03 on Friday. The company has a market capitalization of $23.13 billion, a P/E ratio of -21.90 and a beta of 0.49. Alnylam Pharmaceuticals, Inc. has a one year low of $179.19 and a one year high of $242.97. The stock has a 50 day moving average price of $194.96 and a 200-day moving average price of $200.26.

Insider Activity

In related news, CMO Pushkal Garg sold 3,461 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $185.85, for a total transaction of $643,226.85. Following the sale, the chief marketing officer now owns 8,511 shares in the company, valued at approximately $1,581,769.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 4,057 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $753,993.45. Following the sale, the chief executive officer now owns 35,216 shares in the company, valued at $6,544,893.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 3,461 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $643,226.85. Following the completion of the sale, the chief marketing officer now owns 8,511 shares in the company, valued at approximately $1,581,769.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,144 shares of company stock worth $2,806,347. 1.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $240.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 4th. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $247.00 to $233.00 in a research report on Wednesday, July 26th. Chardan Capital reiterated a “buy” rating and set a $250.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

Get Our Latest Research Report on ALNY

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.